EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, THURSDAY, APRIL 20, 2023
MINNEAPOLIS – The drug atogepant may help prevent migraines for people who have had no success with other preventive drugs, according to a preliminary study released April 20, 2023, which will be presented at the American Academy of Neurology’s 75th Annual Meeting being held in person in Boston and live online from April 22-27, 2023. The study involved people with episodic migraine, which is defined as having up to 14 headache days per month with migraine characteristics.
Atogepant is a calcitonin gene-related peptide receptor antagonist, or CGRP inhibitor. CGRP is a protein that plays a key role in starting the migraine process.
“These results are exciting, as migraine can be debilitating, and this treatment led to fewer days with migraine for people who had already tried up to four other types of drugs to prevent migraine and either had no improvement or had side effects that outweighed any benefits,” said study author Patricia Pozo-Rosich, MD, PhD, at Vall d’Hebron University Hospital in Barcelona, Spain.
The study involved 309 people who had at least four migraine days during the month before the study and who had tried at least two classes of drugs for preventing migraine without improvement. Of those, 44% had previously taken three or more classes of preventive drugs with no success.
For the study, half of the participants took 60 milligrams of atogepant once a day as a pill and the other half took a placebo for 12 weeks.
Those taking the drug had an average of four fewer days with migraine per month from the start of the study to the end, while those taking the placebo had about two fewer days with migraine per month.
Those taking the drug also showed improvement compared to those taking the placebo in how often they needed to take medication to stop a migraine attack and in how many people had a reduction of 50% or higher in how many days per month they had migraines.
The most common side effects were constipation, which occurred in 10% of those taking atogepant and 3% of those taking the placebo, and nausea, which occurred in 7% of those taking the drug and 3% of those taking the placebo.
“People who thought they may not find a way to prevent and treat their migraines may have hope of finding relief with a tolerable oral easy-to-use drug,” Pozo-Rosich said. “This treatment was safe, well-tolerated and effective for people with difficult-to-treat migraine.”
A limitation of the study was the relatively short length of three months. Pozo-Rosich added that more research will be needed to assess the long-term efficacy and safety of atogepant.
The study was supported by AbbVie, the maker of atogepant.
Learn more about migraine at BrainandLife.org, home of the American Academy of Neurology’s free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life® on Facebook, Twitter and Instagram.
When posting to social media channels about this research, we encourage you to use the American Academy of Neurology’s Annual Meeting hashtag #AANAM.
The American Academy of Neurology is the world’s largest association of neurologists and neuroscience professionals, with over 40,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, concussion, Parkinson’s disease and epilepsy.
For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
Dr. Cristina Tassorelli will present the study findings at 6:06 p.m. ET, Tuesday, April 25, in room 253AB at the Boston Convention and Exhibition Center.
Please send an email to media@aan.com to schedule an advance interview.
Emerging Science abstracts are embargoed until 12:01 a.m., ET, Friday, April 21, 2023, unless otherwise noted by the Academy’s Media and Public Relations Department.
To access Non-emerging Science abstracts to be presented at the 2023 AAN Annual Meeting, visit https://www.aan.com/events/annual-meeting-abstracts-awards.
END
New drug may help prevent migraine for difficult cases
2023-04-20
(Press-News.org)
ELSE PRESS RELEASES FROM THIS DATE:
ChatGPT is still no match for humans when it comes to accounting
2023-04-20
Last month, OpenAI launched its newest AI chatbot product, GPT-4. According to the folks at OpenAI, the bot, which uses machine learning to generate natural language text, passed the bar exam with a score in the 90th percentile, passed 13 of 15 AP exams and got a nearly perfect score on the GRE Verbal test.
Inquiring minds at BYU and 186 other universities wanted to know how OpenAI’s tech would fare on accounting exams. So, they put the original version, ChatGPT, to the test. The researchers ...
Researchers reveal a map to study novel form of cell-to-cell communication
2023-04-20
An international team led by researchers at Baylor College of Medicine with the National Institutes of Health Extracellular RNA Communication Consortium and the Bogdan Mateescu laboratory at the ETH Zürich and University of Zürich has developed a new powerful resource to study extracellular RNA (exRNA), a novel form of cell-to-cell communication. The study, published in the journal Cell Genomics, lays the foundation to examine how exRNA and its carrier proteins found in bodily fluids function in a healthy as well as a diseased setting, potentially providing a means to accurately implement early ...
ORNL’s Lupini elected fellow of the Microscopy Society of America
2023-04-20
Andrew Lupini, a scientist and inventor at the Department of Energy’s Oak Ridge National Laboratory, has been elected Fellow of the Microscopy Society of America.
MSA fellows are senior distinguished members who have made significant contributions to the advancement of microscopy and microanalysis through scientific achievement and service to the scientific community and the society. Lupini was one of only four scientists named an MSA Fellow this year.
Lupini was cited “for foundational contribution of theory and practice ...
Purdue Ventures invests in antibody-based cancer therapeutics company
2023-04-20
WEST LAFAYETTE, Ind. – Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000 in TRIO Pharmaceuticals Inc., a cancer immunotherapeutics startup founded by a Purdue University biophysics and structural biology alumnus. The company’s antibody-based therapeutics strengthens the body’s defense, the immune system, to eradicate cancer.
Purdue Ventures’ investment is part of a larger $2.2 million series seed-funding ...
Jefferson Lab stays gold by staying green
2023-04-20
NEWPORT NEWS, VA – Finding ways to purchase sustainable products for the work of science has yielded another golden award. The U.S. Department of Energy's Thomas Jefferson National Accelerator Facility has been recognized with a gold-level GreenBuy Award for its purchase of environmentally friendly products in fiscal year 2022.
The GreenBuy Award Program honors DOE sites that go beyond the minimum requirements for purchasing products that are energy efficient, water efficient and recycled. Participating sites can qualify for three levels of the award: gold, silver and bronze.
“The award is to show our mindset is ...
Evolution of two contagious cancers affecting Tasmanian devils underlines unpredictability of disease threat
2023-04-20
PRESS RELEASE FROM THE UNIVERSITY OF CAMBRIDGE
EMBARGOED UNTIL 19:00 BST LONDON TIME/14:00 US EASTERN TIME THURSDAY, 20 APRIL 2023
Paper and photos available at: https://drive.google.com/drive/folders/1YaEEaTCCMRt85NXmCSpeO15YOrIRaXpO?usp=share_link
Transmissible cancers, which occur only rarely in the animal kingdom, are spread by the transfer of living cancer cells. In the case of Tasmanian devils, the cells are transferred through biting – a behaviour that is common in devils especially in fights over mates and food.
Tasmanian devils are susceptible to two fatal transmissible cancers called devil facial ...
A gene involved in Down syndrome puts the brakes on neurons' activity in mice, new study shows
2023-04-20
Researchers from the University of Michigan have found that an extra copy of a gene in Down syndrome patients causes improper development of neurons in mice.
The gene in question, called Down syndrome cell adhesion molecule, or DSCAM, is also implicated in other human neurological conditions, including autism spectrum disorders, bipolar disorder and intractable epilepsy.
The cause of Down syndrome is known to be an extra copy of chromosome 21, or trisomy 21. But because this ...
Cracking the case of mitochondrial repair and replacement in metabolic stress
2023-04-20
LA JOLLA (April 20, 2023)—Scientists often act as detectives, piecing together clues that alone may seem meaningless but together crack the case. Professor Reuben Shaw has spent nearly two decades piecing together such clues to understand the cellular response to metabolic stress, which occurs when cellular energy levels dip. Whether energy levels fall because the cell’s powerhouses (mitochondria) are failing or due to a lack of necessary energy-making supplies, the response is the same: get rid of the damaged mitochondria and create new ones.
Now, in a study published in Science on April 20, 2023, Shaw and team cracked ...
The climate crisis and biodiversity crisis can’t be approached as two separate things
2023-04-20
Human beings have massively changed the Earth system. Greenhouse-gas emissions produced by human activities have caused the global mean temperature to rise by more than 1.1 degrees Celsius compared to the preindustrial era. And every year, there are additional emissions of carbon dioxide, methane and other greenhouse gases, currently amounting to more than 55 gigatonnes of carbon dioxide equivalent. This unprecedented climate crisis has consequences for the entire planet – the distribution of precipitation ...
Economic growth alone is not enough to eliminate rabies
2023-04-20
Economic growth alone may not be enough to deliver the internationally agreed target to end human deaths from dog mediated rabies, according to new research from the University of Surrey. The study identifies that targeting vulnerable populations and improving responsible pet ownership are urgently needed to eradicate the deadly disease, which has strong associations with poverty.
In a landmark study, Surrey researchers investigated whether incidences of rabies are an inevitable consequence of poverty or whether other measures of development, such as healthcare access, can play a role in tackling this preventable disease.
Dr ...